451 related articles for article (PubMed ID: 10848876)
21. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).
Olivennes F; Belaisch-Allart J; Emperaire JC; Dechaud H; Alvarez S; Moreau L; Nicollet B; Zorn JR; Bouchard P; Frydman R
Fertil Steril; 2000 Feb; 73(2):314-20. PubMed ID: 10685535
[TBL] [Abstract][Full Text] [Related]
22. [Suppression of endogenous LH increase in ovarian stimulation with the GnRH antagonist Cetrorelix].
Diedrich K; Diedrich C; Santos E; Bauer O; Zoll C; al-Hasani S; Reissmann T; Krebs D; Klingmüller D
Geburtshilfe Frauenheilkd; 1994 Apr; 54(4):237-40. PubMed ID: 8013860
[TBL] [Abstract][Full Text] [Related]
23. The role of gonadotropin-releasing hormone antagonists in in vitro fertilization.
Diedrich K; Ludwig M; Felberbaum RE
Semin Reprod Med; 2001 Sep; 19(3):213-20. PubMed ID: 11679902
[TBL] [Abstract][Full Text] [Related]
24. Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?
Chen HJ; Lin YH; Hsieh BC; Seow KM; Hwang JL; Tzeng CR
J Assist Reprod Genet; 2006 Jun; 23(6):289-92. PubMed ID: 16865530
[TBL] [Abstract][Full Text] [Related]
25. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
26. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
[TBL] [Abstract][Full Text] [Related]
27. Oxytocin is not important for the control of gonadotrophin secretion in the late follicular phase of the cycle.
Vanakara P; Dafopoulos K; Papastergiopoulou L; Kallitsaris A; Papageorgiou I; Messinis IE
Clin Endocrinol (Oxf); 2007 Jun; 66(6):816-21. PubMed ID: 17408422
[TBL] [Abstract][Full Text] [Related]
28. GnRH antagonists in ovarian stimulation for IVF.
Tarlatzis BC; Fauser BC; Kolibianakis EM; Diedrich K; Rombauts L; Devroey P
Hum Reprod Update; 2006; 12(4):333-40. PubMed ID: 16567347
[TBL] [Abstract][Full Text] [Related]
29. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle.
Fluker MR; Marshall LA; Monroe SE; Jaffe RB
J Clin Endocrinol Metab; 1991 Apr; 72(4):912-9. PubMed ID: 2005218
[TBL] [Abstract][Full Text] [Related]
30. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.
Lee TH; Wu MY; Chen HF; Chen MJ; Ho HN; Yang YS
Fertil Steril; 2005 Jun; 83(6):1700-7. PubMed ID: 15950639
[TBL] [Abstract][Full Text] [Related]
31. Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels.
Huirne JA; van Loenen AC; Schats R; McDonnell J; Hompes PG; Schoemaker J; Homburg R; Lambalk CB
Hum Reprod; 2004 Oct; 19(10):2206-15. PubMed ID: 15333605
[TBL] [Abstract][Full Text] [Related]
32. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
[TBL] [Abstract][Full Text] [Related]
33. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF.
Lainas T; Zorzovilis J; Petsas G; Stavropoulou G; Cazlaris H; Daskalaki V; Lainas G; Alexopoulou E
Hum Reprod; 2005 Sep; 20(9):2426-33. PubMed ID: 15946995
[TBL] [Abstract][Full Text] [Related]
34. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
Hayes FJ; Taylor AE; Martin KA; Hall JE
J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study.
Cédrin-Durnerin I; Grange-Dujardin D; Laffy A; Parneix I; Massin N; Galey J; Théron L; Wolf JP; Conord C; Clément P; Jayot S; Hugues JN
Hum Reprod; 2004 Sep; 19(9):1979-84. PubMed ID: 15192072
[TBL] [Abstract][Full Text] [Related]
36. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
Levi-Setti PE; Cavagna M; Bulletti C
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
[TBL] [Abstract][Full Text] [Related]
37. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
[TBL] [Abstract][Full Text] [Related]
38. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
Diedrich K; Diedrich C; Santos E; Zoll C; al-Hasani S; Reissmann T; Krebs D; Klingmüller D
Hum Reprod; 1994 May; 9(5):788-91. PubMed ID: 7929723
[TBL] [Abstract][Full Text] [Related]
39. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
40. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
